KBP BioSciences submitted IND of KBP-7072 to the cFDA

Jinan, China and Princeton, New Jersey, USA (May 2015) KBP BioSciences, a clinical stage biotech company with operations in China, US, and Singapore, today announced that the China FDA (cFDA) accepted an Initial New Drug Application (IND) for its experimental drug KBP-7072 for the potential treatment of serious bacterial infections.
KBP-7072 is a next generation tetracycline targeting bacterial resistance that has become global epidemic. KBP-7072 was shown in In Vitro studies to be very effective against a broad spectrum of bacteria, including resistant strains, MRSA, MRSE, PRSP, VRE, anaerobic strains, among others. These properties makes KBP-7072 a promising agent in combating the resistant trends.
Just about a month ago, the US FDA granted approval to KBP BioSciences to commence Phase I clinical trial with KBP-7072. “KBP BioSciences is dedicated to bring innovative medicines to patients across the globe. This new submission to the cFDA is another indication of our commitment to Chinese patients”
The cFDA will review the application package and determine if it meets all the requirements under Chinese laws.